Our new state-of-the-art, cGMP-compliant multi-vector process development facility is now open!
December 7, 2021 – Our deep expertise in development and manufacture of viral vectors coupled with this new facility and equipment will accelerate our partners’ abilities to advance life-saving therapies into the clinic.
The lab will deliver a full suite of process development capabilities to support cGMP and commercial readiness, upstream and downstream process improvements, research grade and preclinical vector production, and analytical assay development and validation from the site. Learn more about the facility’s capabilities here.
